These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29855615)

  • 21. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
    Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.
    Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Zhao X; Yu Y; Zhang H; Xu F; Tian Y
    J Exp Clin Cancer Res; 2021 Aug; 40(1):267. PubMed ID: 34433460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TX99 Is a Neutralizing Monoclonal Antibody Against Mouse TIGIT.
    Nakamura Y; Naito K; Yamashita-Kanemaru Y; Komori D; Hirochika R; Shibuya A; Shibuya K
    Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):105-109. PubMed ID: 29648914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia.
    Li J; Whelan S; Kotturi MF; Meyran D; D'Souza C; Hansen K; Liang S; Hunter J; Trapani JA; Neeson PJ
    Haematologica; 2021 Dec; 106(12):3115-3124. PubMed ID: 33147937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The N-linked glycosylations of TIGIT Asn
    Lin YX; Hung MC; Hsu JL; Hsu JM
    Biochem Biophys Res Commun; 2021 Jul; 562():9-14. PubMed ID: 34030043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients.
    Kong Y; Zhu L; Schell TD; Zhang J; Claxton DF; Ehmann WC; Rybka WB; George MR; Zeng H; Zheng H
    Clin Cancer Res; 2016 Jun; 22(12):3057-66. PubMed ID: 26763253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
    Laszlo GS; Gudgeon CJ; Harrington KH; Dell'Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB
    Blood; 2014 Jan; 123(4):554-61. PubMed ID: 24311721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristic of TIGIT and DNAM-1 Expression on Foxp3+
    Jin Z; Ye W; Lan T; Zhao Y; Liu X; Chen J; Lai J; Chen S; Zhong X; Wu X
    Biomed Res Int; 2020; 2020():4612952. PubMed ID: 32802845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
    Herrmann M; Krupka C; Deiser K; Brauchle B; Marcinek A; Ogrinc Wagner A; Rataj F; Mocikat R; Metzeler KH; Spiekermann K; Kobold S; Fenn NC; Hopfner KP; Subklewe M
    Blood; 2018 Dec; 132(23):2484-2494. PubMed ID: 30275109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
    Harrington KH; Gudgeon CJ; Laszlo GS; Newhall KJ; Sinclair AM; Frankel SR; Kischel R; Chen G; Walter RB
    PLoS One; 2015; 10(8):e0135945. PubMed ID: 26305211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
    Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; Slootstra JW; Baeuerle PA; Kufer P; Rattel B
    Mol Cancer Ther; 2014 Jun; 13(6):1549-57. PubMed ID: 24674885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
    Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
    Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.
    Zhu L; Kong Y; Zhang J; Claxton DF; Ehmann WC; Rybka WB; Palmisiano ND; Wang M; Jia B; Bayerl M; Schell TD; Hohl RJ; Zeng H; Zheng H
    J Hematol Oncol; 2017 Jun; 10(1):124. PubMed ID: 28629373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Higher TIGIT
    Jin Z; Lan T; Zhao Y; Du J; Chen J; Lai J; Xu L; Chen S; Zhong X; Wu X; Li Y
    Immunol Invest; 2022 Jan; 51(1):40-50. PubMed ID: 32819181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
    J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT.
    Zhou X; Du J; Zhou X; Niu X; Li W; Chen C; Lv S; Wu A; Gou S; Sun Y; Zhai W; Qiu L; Qi Y; Zhao W; Gao Y
    Cell Commun Signal; 2021 Feb; 19(1):12. PubMed ID: 33557880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.
    Chiang EY; Mellman I
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
    Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
    Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the "PVR-TIGIT axis" with immune checkpoint therapies.
    Gorvel L; Olive D
    F1000Res; 2020; 9():. PubMed ID: 32489646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway.
    Ma B; Duan X; Zhou Q; Liu J; Yang X; Zhang D; Yang S; Du Y; Li H; Su C
    J Cell Mol Med; 2019 Jul; 23(7):4514-4522. PubMed ID: 31090213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.